Clinical Trial Update: Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 trial comparing biosimilar denosumab (Arylia) to Prolia in improving bone mineral density in osteoporotic postmenopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Arylia (denosumab)
• Prolia (denosumab)

Snippet

Sponsor: AryoGen Pharmed Co. | Conditions: Osteoporosis | Phase 3 | Status: UNKNOWN